BioNotebook: Vertex/BioAxone and four other deals; three VC updates, three public offerings

Vertex Pharmaceuticals said in its annual report filed recently with the US Securities and Exchange Commission (SEC) that it has licensed VX-210 (formerly Cethrin) for spinal cord injuries from BioAxone Biosciences for $10m up front and up to $90m in development and regulatory milestone payments and license continuation fees.

Vertex Pharmaceuticals said in its annual report filed recently with the US Securities and Exchange Commission (SEC) that it has licensed VX-210 (formerly Cethrin) for spinal cord injuries from BioAxone Biosciences for $10m up front and up to $90m in development and regulatory milestone payments and license continuation fees.

Boston-based Vertex said it closed the deal with BioAxone, a private company in nearby Cambridge, Massachusetts in October, but it...

Scrip Podcast

Keep up with the top pharma business news of the week. On the go.

Scrip brings you a weekly bulletin of top picks.

More from Archive

More from Scrip